Eiger Biopharmaceuticals (EIGR) Received its Third Buy in a Row


After Ladenburg Thalmann & Co. and Jefferies gave Eiger Biopharmaceuticals (NASDAQ: EIGR) a Buy rating last month, the company received another Buy, this time from Wedbush. Analyst Liana Moussatos reiterated a Buy rating on Eiger Biopharmaceuticals today and set a price target of $32.00. The company’s shares closed last Tuesday at $11.08.

According to TipRanks.com, Moussatos is a 4-star analyst with an average return of 9.2% and a 49.5% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as Catabasis Pharmaceuticals, Global Blood Therapeutics, and BioMarin Pharmaceutical.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Eiger Biopharmaceuticals with a $26.50 average price target, a 140.9% upside from current levels. In a report released yesterday, Ladenburg Thalmann & Co. also maintained a Buy rating on the stock with a $28.00 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $15.82 and a one-year low of $4.55. Currently, Eiger Biopharmaceuticals has an average volume of 419.9K.

Based on the recent corporate insider activity of 19 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of EIGR in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Eiger BioPharmaceuticals, Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of well-characterized drugs for life-threatening, rare and ultra-rare diseases with high unmet medical needs and no approved therapies. The company was founded by David A. Cory on November 6, 2008 and is headquartered in Palo Alto, CA.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts